Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women

Pilar Peris, Elizabeth J. Atkinson, Mario Gössl, Trevor L. Kane, Louise K. McCready, Amir Lerman, Sundeep Khosla, Ulrike I. McGregor

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Objective: To evaluate whether bisphosphonates modulate vascular calcification by a modification in endothelial progenitor cells (EPCs) coexpressing osteoblastic surface markers and genes. Patients and Methods: We performed a double-blind, randomized study of 20 healthy, early postmenopausal women (from February 1, 2008, through July 31, 2008) treated with placebo or risedronate sodium (35 mg/wk) for 4 months. Peripheral blood was collected at baseline and 4 months to determine serum inflammatory markers, osteoprotegerin, and receptor activator of nuclear factor-κB ligand levels and bone turnover markers. Peripheral blood mononuclear cells were stained for EPC surface markers (CD34, CD133, and vascular endothelial growth factor receptor/kinase insert domain receptor) and osteoblast markers (osteocalcin, alkaline phosphatase, and Stro-1). Results: Risedronate treatment resulted in a significant down-regulation of gene sets for osteoblast differentiation and proliferation in EPCs with a trend of decreasing EPCs coexpressing osteocalcin. Conclusion: Our findings indicate that bisphosphonate treatment down-regulates the expression of osteogenic genes in EPCs and suggest a possible mechanism by which bisphosphonates may inhibit vascular calcification.

Original languageEnglish (US)
Pages (from-to)46-55
Number of pages10
JournalMayo Clinic proceedings
Volume88
Issue number1
DOIs
StatePublished - Jan 2013

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women'. Together they form a unique fingerprint.

Cite this